Profile data is unavailable for this security.
About the company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
- Revenue in USD (TTM)295.39m
- Net income in USD-137.25m
- Incorporated2013
- Employees375.00
- LocationDenali Therapeutics Inc161 Oyster Point BlvdSOUTH SAN FRANCISCO 94080-1910United StatesUSA
- Phone+1 (650) 866-8548
- Fax+1 (302) 655-5049
- Websitehttps://www.denalitherapeutics.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.62bn | 610.00 | -- | 5.63 | 292.61 | 3.22 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 2.76bn | 251.00 | -- | 3.11 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
SpringWorks Therapeutics Inc | 26.45m | -339.07m | 2.76bn | 305.00 | -- | 4.86 | -- | 104.38 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
Azenta Inc | 651.76m | -152.26m | 2.78bn | 3.40k | -- | 1.27 | -- | 4.26 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
TG Therapeutics Inc | 289.33m | 41.20m | 2.83bn | 284.00 | 83.04 | 17.68 | 68.40 | 9.78 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Arcellx Inc | 131.66m | -50.54m | 2.85bn | 130.00 | -- | 5.71 | -- | 21.64 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Amicus Therapeutics, Inc. | 423.49m | -147.07m | 2.92bn | 517.00 | -- | 22.32 | -- | 6.89 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Biohaven Ltd | 0.00 | -517.18m | 3.02bn | 239.00 | -- | 9.27 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
Denali Therapeutics Inc | 295.39m | -137.25m | 3.10bn | 375.00 | -- | 2.13 | -- | 10.50 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
Arrowhead Pharmaceuticals Inc | 35.47m | -470.79m | 3.13bn | 525.00 | -- | 6.47 | -- | 88.30 | -4.24 | -4.24 | 0.3189 | 3.90 | 0.0384 | -- | -- | 67,567.62 | -51.72 | -20.02 | -57.39 | -24.65 | -- | -- | -1,346.13 | -61.79 | -- | -80.00 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
Dyne Therapeutics Inc | 0.00 | -257.40m | 3.44bn | 143.00 | -- | 6.31 | -- | -- | -3.97 | -3.97 | 0.00 | 5.49 | 0.00 | -- | -- | 0.00 | -63.48 | -52.81 | -67.12 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
Guardant Health Inc | 603.73m | -460.90m | 3.53bn | 1.78k | -- | 51.49 | -- | 5.85 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
Crinetics Pharmaceuticals Inc | 1.97m | -235.46m | 3.59bn | 290.00 | -- | 4.09 | -- | 1,819.28 | -3.77 | -3.77 | 0.0315 | 11.14 | 0.0031 | -- | 0.3653 | 6,806.90 | -35.57 | -42.53 | -37.86 | -45.36 | -- | -- | -11,641.13 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 31 Mar 2024 | 14.04m | 9.85% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 10.63m | 7.46% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 9.30m | 6.52% |
Wellington Management Co. LLPas of 31 Mar 2024 | 8.27m | 5.80% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.32m | 4.43% |
Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 6.05m | 4.24% |
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 2024 | 5.71m | 4.00% |
Crestline Management LPas of 31 Mar 2024 | 5.21m | 3.65% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 3.73m | 2.62% |
Geode Capital Management LLCas of 31 Mar 2024 | 2.76m | 1.94% |